Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.
Advertisement

Related Content

UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
UCB Inks Buyback-Option Deal With Wilex For Oncology Lineup
UCB Inks Buyback-Option Deal With Wilex For Oncology Lineup
UCB To SHAPE Up With Cost-Cutting Plan, Two Years After Schwarz Buy
UCB Recalls Neupro Patches; U.S. Projected Out Of Stock By Late April
Neupro Patch Could See Restless Legs Indication In Second Half 2008
Neupro Patch Could See Restless Legs Indication In Second Half 2008
Schwarz Pharma’s Neupro Patch Gets FDA Nod For Early Parkinson’s Disease

Topics

Advertisement
UsernamePublicRestriction

Register

PS067151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel